JP2013533875A - 免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体 - Google Patents

免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体 Download PDF

Info

Publication number
JP2013533875A
JP2013533875A JP2013518254A JP2013518254A JP2013533875A JP 2013533875 A JP2013533875 A JP 2013533875A JP 2013518254 A JP2013518254 A JP 2013518254A JP 2013518254 A JP2013518254 A JP 2013518254A JP 2013533875 A JP2013533875 A JP 2013533875A
Authority
JP
Japan
Prior art keywords
facviia
immunoglobulin
region
facvii
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533875A5 (enExample
Inventor
ハエ ソン，デ
イン リム，スン
フワン キム，チャン
カップ ホン，スン
ソン イム，デ
チャン クウォン，セ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of JP2013533875A publication Critical patent/JP2013533875A/ja
Publication of JP2013533875A5 publication Critical patent/JP2013533875A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
JP2013518254A 2010-06-30 2011-06-30 免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体 Pending JP2013533875A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0062860 2010-06-30
KR1020100062860A KR20120002129A (ko) 2010-06-30 2010-06-30 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체
PCT/KR2011/004796 WO2012002745A2 (en) 2010-06-30 2011-06-30 Factor viia complex using an immunoglobulin fragment

Publications (2)

Publication Number Publication Date
JP2013533875A true JP2013533875A (ja) 2013-08-29
JP2013533875A5 JP2013533875A5 (enExample) 2014-06-26

Family

ID=45402578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518254A Pending JP2013533875A (ja) 2010-06-30 2011-06-30 免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体

Country Status (8)

Country Link
US (1) US20130095090A1 (enExample)
EP (1) EP2588142A2 (enExample)
JP (1) JP2013533875A (enExample)
KR (1) KR20120002129A (enExample)
CN (1) CN103025358A (enExample)
AR (1) AR082032A1 (enExample)
TW (1) TWI443106B (enExample)
WO (1) WO2012002745A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512096A (ja) * 2016-01-21 2019-05-09 プロテイン ダイナミック ソリューションズ インコーポレイテッドＰｒｏｔｅｉｎ Ｄｙｎａｍｉｃ Ｓｏｌｕｔｉｏｎｓ，Ｉｎｃ． スペクトルデータ解析の方法およびシステム

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406606A (pt) * 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
KR20160143820A (ko) * 2014-04-11 2016-12-14 시에스엘 리미티드 출혈의 예방 및 치료를 위한 반감기 연장 인자 ｆｖｉｉａ 단백질 및 이의 투약 용법
KR101892687B1 (ko) 2017-05-18 2018-08-28 세종대학교산학협력단 하이드라진 연료전지용 전극과 이를 포함하는 막 전극 접합체 및 연료전지
CN111849945B (zh) * 2019-04-25 2024-11-29 正大天晴药业集团股份有限公司 人凝血因子VIIa的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502252A (ja) * 2003-08-14 2007-02-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
JP2007509843A (ja) * 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
JP2007536211A (ja) * 2003-11-13 2007-12-13 ハンミ ファーム．インダストリー カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2010011096A2 (en) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515508A (ja) * 2005-08-19 2009-04-16 ネオス テクノロジーズ インコーポレイテッド グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ
WO2007140282A1 (en) * 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
ES2531934T3 (es) * 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502252A (ja) * 2003-08-14 2007-02-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
JP2007509843A (ja) * 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
JP2007536211A (ja) * 2003-11-13 2007-12-13 ハンミ ファーム．インダストリー カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2010011096A2 (en) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512096A (ja) * 2016-01-21 2019-05-09 プロテイン ダイナミック ソリューションズ インコーポレイテッドＰｒｏｔｅｉｎ Ｄｙｎａｍｉｃ Ｓｏｌｕｔｉｏｎｓ，Ｉｎｃ． スペクトルデータ解析の方法およびシステム
JP7426193B2 (ja) 2016-01-21 2024-02-01 プロテイン ダイナミック ソリューションズ インコーポレイテッド スペクトルデータ解析の方法およびシステム

Also Published As

Publication number Publication date
AR082032A1 (es) 2012-11-07
KR20120002129A (ko) 2012-01-05
CN103025358A (zh) 2013-04-03
WO2012002745A2 (en) 2012-01-05
TWI443106B (zh) 2014-07-01
TW201217396A (en) 2012-05-01
EP2588142A2 (en) 2013-05-08
US20130095090A1 (en) 2013-04-18
WO2012002745A3 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
US9364520B2 (en) Factor VIII conjugates
TWI802396B (zh) 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN103974716B (zh) 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
TW201201831A (en) Long-acting interferon beta formulation using immunoglobulin fragment
KR20140090703A (ko) 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
HK1207591A1 (en) Chimeric clotting factors
CN105229025B (zh) 位点特异性胰岛素缀合物
JP2013533875A (ja) 免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
JP2015514704A (ja) 持続型ヒト成長ホルモン結合体の高濃度液剤
JP2020528756A (ja) イズロン酸−２−スルファターゼ結合体
KR20180031775A (ko) 긴 반감기 응집 복합체와 관련된 방법 및 조성물
AU2012203813B2 (en) Site-directed modification of FVIII
HK1196565A (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
NZ623726B2 (en) Blood coagulation factor ? and ?a derivatives, conjugates and complexes comprising the same, and use thereof
HK1217202B (zh) 位点特异性胰岛素缀合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150123

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20150209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150616